Published on
14:18 GMT
FDA Advisory Panel Calls for Revised Class Labeling for Menopausal Hormone Replacement Therapy
An advisory panel convened by the FDA on July 17 signaled a major shift in federal thinking about menopausal hormone therapy (HT). The panel, composed of leading clinicians and researchers in gynecology, cardiology, endocrinology, and women’s health, …
Source:
Patient Care
-
Pending
